SuperworthiBio revenue IBIO
Sales by quarter and over the last twelve months, from 2011.
- Last 12 months, to Mar 31, 2026
- $300K
- Latest quarter, Q3 FY26
- $0
- Fiscal year 2025
- $400K
- +78% on the year before
iBio's revenue was $300K over the twelve months to Mar 31, 2026, down 20% on a year earlier.
In its latest quarter, Q3 FY26, it was $0.
Over the five fiscal years to FY2025 it shrank 28% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $400K | +78% |
| FY2024 | $225K | −88% |
| FY2022 | $1.9M | −21% |
| FY2021 | $2.4M | +45% |
| FY2020 | $1.6M | −19% |
| FY2019 | $2M | +355% |
| FY2018 | $444K | +13% |
| FY2017 | $394K | −58% |
| FY2016 | $948K | −49% |
| FY2015 | $1.9M | +803% |
| FY2014 | $205K | −80% |
| FY2013 | $1M | −21% |
| FY2012 | $1.3M | n/a |
| FY2011 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q3 FY26 | $0 | n/a | $300K | |
| Q2 FY26 | $0 | −100% | $300K | |
| Q1 FY26 | $100K | n/a | $500K | |
| Q4 FY25 | $200K | +14% | $400K | |
| Q3 FY25 | $0 | n/a | $375K | |
| Q2 FY25 | $200K | n/a | $375K | |
| Q1 FY25 | $0 | −100% | $175K | |
| Q4 FY24 | $175K | n/a | $225K | |
| Q3 FY24 | $0 | n/a | n/a | |
| Q2 FY24 | $0 | n/a | n/a | |
| Q1 FY24 | $50K | n/a | n/a | |
| Q3 FY23 | $0 | −100% | $0 |
Against its peers
Companies in Drug Manufacturers - General nearest iBio's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| IBIOiBio | n/m | |
| ATNMActinium Pharmaceuticals | n/m | |
| SPROSpero Therapeutics | $47M | −3% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| Peer median | $182.6M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on iBio
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.